Tempus AI Inc. (NASDAQ: TEM) and Predicta Biosciences announced a collaboration to commercialize a whole-genome sequencing assay for blood cancer detection and monitoring. The co-branded test, called GenoPredicta, analyzes genetic material from peripheral blood or bone marrow samples.

The assay combines flow cytometry with whole-genome sequencing to detect genetic alterations from as few as 50 tumor cells, achieving sensitivity of one in a million cells, according to the companies. This level of detection enables testing in cases with low tumor burden that might not qualify for traditional testing methods.

GenoPredicta is currently available to Tempus' life sciences partners for research and clinical development programs. The test has received clinical validation for multiple myeloma and other plasma cell disorders, while remaining available for research use only in other cancer types.

The technology was developed based on research by Dr. Irene Ghobrial, scientific co-founder of Predicta Biosciences, who has focused on early detection methods for blood cancers.

"By joining forces with Tempus, we are delivering unprecedented sensitivity and clarity to researchers - enabling the potential for earlier detection, smarter treatment decisions, and a deeper understanding of disease biology from a single assay," said Brian McKernan, CEO of Predicta Biosciences.

Kate Sasser, Chief Scientific Officer at Tempus, stated that the assay "delivers 100% concordance between peripheral blood and bone marrow" and can "provide these deep insights while sparing patients from biopsies."

The collaboration aims to expand market adoption of the testing technology for clinical trial applications. Information was provided in a company press release.